INmune Bio Clears Key Manufacturing Hurdle for Rare Disease Therapy
Event summary
- INmune Bio completed commercial manufacturing of its CORDStrom™ platform at the CGT Catapult facility in Stevenage, UK.
- The milestone supports planned Phase 3 trials and regulatory filings for Ebstrocel™, a treatment for recessive dystrophic epidermolysis bullosa (RDEB).
- Process meets MHRA, EMA, and FDA standards, including infectious disease testing in US-CLIA-accredited labs.
- Company aligns with MHRA's draft rare disease therapies regulatory framework for flexible evidence generation.
The big picture
INmune Bio's manufacturing achievement reduces a critical operational risk for cell therapy commercialization. The alignment with MHRA's flexible regulatory framework could accelerate rare disease therapy approvals, but success hinges on maintaining this momentum through Phase 3 trials and cross-border filings.
What we're watching
- Regulatory Alignment
- Whether INmune Bio can sustain momentum with MHRA's evolving rare disease framework ahead of planned filings.
- Execution Risk
- The pace at which commercial manufacturing scales to support global registration and future supply demands.
- Market Dynamics
- How competitive positioning shifts as INmune Bio advances toward Phase 3 trials in the ultra-rare disease space.
Related topics